Volume 24, Issue 5 p. 396-399
Brief Report

Adding urine and saliva toxicology to SBIRT for drug screening of new patients

Stephen Magura PhD

Corresponding Author

Stephen Magura PhD

Western Michigan University, Kalamazoo, Michigan

Address correspondence to: Magura, The Evaluation Center, Western Michigan University, 1903 W. Michigan Ave., Kalamazoo, MI 49008.

E-mail: [email protected]

Search for more papers by this author
Eric D. Achtyes MD

Eric D. Achtyes MD

Cherry Health, Grand Rapids, Michigan

Michigan State University College of Medicine, Grand Rapids, Michigan

Search for more papers by this author
Kristin Batts LMSW

Kristin Batts LMSW

Cherry Health, Grand Rapids, Michigan

Search for more papers by this author
Thomas Platt MD

Thomas Platt MD

Cherry Health, Grand Rapids, Michigan

Search for more papers by this author
Thomas L. Moore LMSW

Thomas L. Moore LMSW

Western Michigan University, Kalamazoo, Michigan

Cherry Health, Grand Rapids, Michigan

Search for more papers by this author
First published: 11 June 2015
Citations: 5
[Correction added on 21 July 2015, after first online publication: The authors affiliations have been corrected.]

Abstract

Background and Objectives

To determine illicit drug use among new patients in primary medical care who denied using “street drugs” during Screening, Brief Intervention and Referral to Treatment (SBIRT).

Methods

96 new patients who denied use of “street drugs” were tested for drugs as part of routine SBIRT screening.

Results

Of those tested, 14.6% of those with urine specimens and 4.1% of those with saliva specimens tested positive for illicit drugs.

Discussion and Conclusions

Drug toxicology can detect unreported illicit drug use during SBIRT screening, with urine being superior to saliva.

Scientific Significance

Drug toxicology can increase the effectiveness of SBIRT screening in primary care medical clinics. (Am J Addict 2015;24:396 –399)

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.